Gene · 8205
Papers2,064
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 2,064
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen. | Oncoscience | 2023 | 37953875 | PubTator, text mining | PubMed |
| MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis. | Proc Natl Acad Sci U S A | 2023 | 37922327 | PubTator, text mining | PubMed |
| Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment. | Asian J Pharm Sci | 2023 | 37920650 | PubTator, text mining | PubMed |
| FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression. | J Exp Clin Cancer Res | 2023 | 37915048 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma. | Sci Rep | 2023 | 37914817 | PubTator, text mining | PubMed |
| The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer. | Front Endocrinol (Lausanne) | 2023 | 37900137 | PubTator, text mining | PubMed |
| The universe of galectin-binding partners and their functions in health and disease. | J Biol Chem | 2023 | 37898403 | PubTator, text mining | PubMed |
| Targeting the Heterogeneous Tumour-Associated Macrophages in Hepatocellular Carcinoma. | Cancers (Basel) | 2023 | 37894344 | PubTator, text mining | PubMed |
| MTH1 Inhibition Alleviates Immune Suppression and Enhances the Efficacy of Anti-PD-L1 Immunotherapy in Experimental Mesothelioma. | Cancers (Basel) | 2023 | 37894329 | PubTator, text mining | PubMed |
| TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages. | J Exp Clin Cancer Res | 2023 | 37891677 | PubTator, text mining | PubMed |
| The 'speck'-tacular oversight of the NLRP3-pyroptosis pathway on gastrointestinal inflammatory diseases and tumorigenesis. | J Biomed Sci | 2023 | 37891577 | PubTator, text mining | PubMed |
| Tumor heterogeneity and tumor-microglia interactions in primary and recurrent IDH1-mutant gliomas. | Cell Rep Med | 2023 | 37883975 | PubTator, text mining | PubMed |
| The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. | Nat Commun | 2023 | 37872170 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Prognostic Value and Immune Infiltration of TFAP2 Family Members in Bladder Cancer from Database and FFPE Sample. | J Cancer | 2023 | 37859819 | PubTator, text mining | PubMed |
| NF-κB signaling in neoplastic transition from epithelial to mesenchymal phenotype. | Cell Commun Signal | 2023 | 37853467 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing reveals pro-invasive cancer-associated fibroblasts in hypopharyngeal squamous cell carcinoma. | Cell Commun Signal | 2023 | 37853464 | PubTator, text mining | PubMed |
| Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. | Mol Cancer | 2023 | 37853437 | PubTator, text mining | PubMed |
| Red Blood Cell-Derived Extracellular Vesicles Display Endogenous Antiviral Effects and Enhance the Efficacy of Antiviral Oligonucleotide Therapy. | ACS Nano | 2023 | 37852618 | PubTator, text mining | PubMed |
| Alveolar macrophages in lung cancer: opportunities challenges. | Front Immunol | 2023 | 37822933 | PubTator, text mining | PubMed |
| Don't eat me/eat me signals as a novel strategy in cancer immunotherapy. | Heliyon | 2023 | 37822610 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8205/papers?page=14